Geraghty Patrick, Eden Edward, Pillai Manju, Campos Michael, McElvaney Noel G, Foronjy Robert F
1 Division of Pulmonary and Critical Care Medicine, Mount Sinai Roosevelt Hospital, New York, New York.
Am J Respir Crit Care Med. 2014 Dec 1;190(11):1229-42. doi: 10.1164/rccm.201405-0872OC.
α1-Antitrypsin (A1AT) was identified as a plasma protease inhibitor; however, it is now recognized as a multifunctional protein that modulates immunity, inflammation, proteostasis, apoptosis, and cellular senescence. Like A1AT, protein phosphatase 2A (PP2A), a major serine-threonine phosphatase, regulates similar biologic processes and plays a key role in chronic obstructive pulmonary disease.
Given their common effects, this study investigated whether A1AT acts via PP2A to alter tumor necrosis factor (TNF) signaling, inflammation, and proteolytic responses in this disease.
PP2A activity was measured in peripheral blood neutrophils from A1AT-deficient (PiZZ) and healthy (PiMM) individuals and in alveolar macrophages from normal (60 mg/kg) and high-dose (120 mg/kg) A1AT-treated PiZZ subjects. PP2A activation was assessed in human neutrophils, airway epithelial cells, and peripheral blood monocytes treated with plasma purified A1AT protein. Similarly, lung PP2A activity was measured in mice administered intranasal A1AT. PP2A was silenced in lung epithelial cells treated with A1AT and matrix metalloproteinase and cytokine production was then measured following TNF-α stimulation.
PP2A was significantly lower in neutrophils isolated from PiZZ compared with PiMM subjects. A1AT protein activated PP2A in human alveolar macrophages, monocytes, neutrophils, airway epithelial cells, and in mouse lungs. This activation required functionally active A1AT protein and protein tyrosine phosphatase 1B expression. A1AT treatment acted via PP2A to prevent p38 and IκBα phosphorylation and matrix metalloproteinase and cytokine induction in TNF-α-stimulated epithelial cells.
Together, these data indicate that A1AT modulates PP2A to counter inflammatory and proteolytic responses induced by TNF signaling in the lung.
α1 -抗胰蛋白酶(A1AT)最初被鉴定为一种血浆蛋白酶抑制剂;然而,现在它被认为是一种多功能蛋白,可调节免疫、炎症、蛋白质稳态、细胞凋亡和细胞衰老。与A1AT类似,蛋白磷酸酶2A(PP2A)作为一种主要的丝氨酸 - 苏氨酸磷酸酶,调节相似的生物学过程,并在慢性阻塞性肺疾病中起关键作用。
鉴于它们的共同作用,本研究调查了A1AT是否通过PP2A来改变该疾病中的肿瘤坏死因子(TNF)信号传导、炎症和蛋白水解反应。
在A1AT缺乏(PiZZ)个体和健康(PiMM)个体的外周血中性粒细胞中,以及在正常剂量(60mg/kg)和高剂量(120mg/kg)A1AT治疗PiZZ受试者的肺泡巨噬细胞中测量PP2A活性。在用血浆纯化的A1AT蛋白处理的人中性粒细胞、气道上皮细胞和外周血单核细胞中评估PP2A的激活情况。同样,在经鼻给予A1AT后的小鼠中测量肺组织PP2A活性。在用A1AT处理的肺上皮细胞中使PP2A沉默,然后在TNF-α刺激后测量基质金属蛋白酶和细胞因子的产生。
与PiMM受试者相比,从PiZZ分离的中性粒细胞中PP2A显著降低。A1AT蛋白在人肺泡巨噬细胞、单核细胞、中性粒细胞、气道上皮细胞和小鼠肺中激活PP2A。这种激活需要功能活性的A1AT蛋白和蛋白酪氨酸磷酸酶1B的表达。A-1AT处理通过PP2A起作用,以防止TNF-α刺激的上皮细胞中p38和IκBα磷酸化以及基质金属蛋白酶和细胞因子的诱导。
总之,这些数据表明A1AT调节PP2A以对抗肺中TNF信号传导诱导的炎症和蛋白水解反应。